Business Context and Reporting Period
Company: SANUWAVE Health, Inc. (SNWV)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Sanuwave is a medical device company focused on regenerative medicine, primarily marketing the UltraMIST® system. This FDA-cleared device uses non-contact, low-frequency ultrasound to treat acute and chronic wounds. The company operates as a single reporting segment with revenues generated primarily in the United States.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 (Restated) | 2024 (Restated) |
|---|---|---|
| Revenue | $44.1 million | $32.6 million |
| Gross Margin | 77% | 75% |
| Operating Income | $4.9 million | $3.8 million |
| Net Income (Loss) | $11.8 million | $(33.1) million |
| Diluted EPS | $0.41 | $(7.41) |
| Cash from Operations | $3.9 million | $2.5 million |
| Cash and Equivalents (End of Period) | $12.0 million | $10.2 million |
| Total Debt (Principal) | $22.2 million | $26.9 million |
Note: 2024 figures have been restated to correct accounting errors. The 2025 net income includes a non-cash gain of $8.1 million from the change in fair value of derivative liabilities and a $5.0 million gain from the sale of patents.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 35% to $44.1 million, driven by a 24% increase in consumable sales volume and a 67% increase in system sales volume. Consumables accounted for 58% of total revenue.
- Profitability Turnaround: The company reported a net income of $11.8 million in 2025 compared to a net loss of $33.1 million in 2024. This $44.9 million swing was largely driven by non-cash changes in derivative liabilities and improved operational performance.
- Debt Refinancing: In September 2025, the company refinanced its senior secured debt with a new $23.0 million term loan and a $5.0 million revolving credit facility from JPMorgan Chase, extending maturities and alleviating prior "going concern" doubts.
- Restatement: The company restated financial statements for 2024 and 2025 quarters due to errors in sales tax accruals and revenue recognition related to extended warranties. This resulted in increased expenses and reduced revenue in prior periods.
Guidance, Outlook, and Risks
Management Commentary & Outlook: Management believes the debt refinancing, positive operating income, and expected cash inflows provide sufficient resources to meet obligations for the next 12 months. The company is focused on profitable growth, expanding its direct sales force, and leveraging the "razor/razor blade" business model. There is no specific numerical guidance provided for 2026 in this filing.
Material Risks & Contingencies:
- Internal Control Weaknesses: The company identified material weaknesses in internal controls over financial reporting related to insufficient accounting resources, revenue recognition, and sales tax compliance. These were not remediated as of December 31, 2025.
- Restatement Impact: Previously issued financial information for 2024 and 2025 quarters should no longer be relied upon due to the restatement of sales tax liabilities and warranty revenue.
- Supplier Concentration: The company relies on single suppliers for most product component materials and finished product assembly, creating supply chain disruption risks.
- Regulatory & Reimbursement: Operations are subject to extensive FDA regulation and third-party reimbursement policies (e.g., CMS Category 1 code 97610). Changes in reimbursement could materially affect demand.
Investor Verification Checklist
- Restatement Details: Verify the specific impact of the sales tax and warranty revenue restatements on the company's historical performance and current liability balances.
- Internal Control Remediation: Monitor the progress of the remediation plan for material weaknesses in internal controls, as failure to remediate could lead to future restatements or reporting failures.
- Debt Covenants: Review the covenants associated with the new JPMorgan Chase credit agreement to ensure ongoing compliance.
- Non-GAAP Adjustments: Scrutinize the Adjusted EBITDA reconciliation, specifically the exclusion of the $8.1 million derivative liability gain and $5.0 million patent sale gain, to understand core operational cash flow.
- Supplier Dependencies: Assess the risk mitigation strategies regarding the single-source suppliers for critical product components.